IP Library Granted Patent US 12,582,796
Granted Patent B2
US 12,582,796 · App. 18/482,460 · Granted Mar 24, 2026

Methods, devices, and systems for improved oxygenation patient monitoring, mixing, and delivery

Inventor: John C. Taube (Raleigh, NC)
Assignee: Vapotherm, Inc.
A61M16/024A61B5/14551A61M16/00A61M16/026A61M16/12A61M2202/0208A61M2205/502A61M2230/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,796
App. No.
18/482,460
Granted
Mar 24, 2026
Kind
B2
Abstract

A computer implemented method is disclosed for providing adaptive control of a gas mixture for delivery to a patient via a separate external gas blender system. The computer implemented method includes receiving first SpO 2 data from a regional oximeter via a regional oximeter interface; determining first PaO 2 data using a first lookup table derived from a first sigmoid shaped oxyhemoglobin dissociation curve; determining a first gas mixture value using the first PaO 2 data; and transmitting first adaptive feedback control data including the first gas mixture value to the separate external gas blender system via a gas blender interface.

Claims (69)

1 . A system for controlling a gas blender system configured to deliver a gas mixture with a target FiO 2 to a patient, the system comprising:

at least one processor electronically coupled to the gas blender system; and

a memory electronically coupled to the at least one processor, the memory containing a set of instructions, wherein the instructions, when executed by the processor, cause the processor to:

receive a target PaO 2 value from a user via a user interface;

receive a first measured SpO 2 value from a pulse oximeter functionally connected to the at least one processor;

convert the first measured SpO 2 value to a first measured PaO 2 value using a first lookup table derived from a sigmoid shaped oxyhemoglobin dissociation curve, the first lookup table stored in the memory;

calculate a first error value as a difference between the first measured PaO 2 and the target PaO 2 ;

process the first error value to determine a first oxygen mixer control value, by executing an algorithm using at least one of proportional values, integral values, or derivative values;

receive a second measured SpO 2 value from a regional oximeter functionally connected to the at least one processor and configured to measure cerebral blood oxygen saturation;

convert the second measured SpO 2 value to a second measured PaO 2 value using a second lookup table derived from a sigmoid shaped oxyhemoglobin dissociation curve, the second lookup table stored in the memory;

calculate a second error value as a difference between the second measured PaO 2 and the target PaO 2 ;

process the second error value to determine a second oxygen mixer control value, by executing an algorithm using at least one of proportional values, integral values, or derivative values;

and

if the system is operating in a first mode, output the first oxygen mixer control value to a blender controller configured to cause the gas blender system to deliver the gas mixture to the patient with the target FiO 2 value, or

if the system is operating in a second mode, output the second oxygen mixer control value to the blender controller configured to cause the gas blender system to deliver the gas mixture to the patient with the target FiO 2 value.

2 . The system of claim 1 , wherein the processing the error value comprises executing the algorithm using proportional values, integral values, and derivative values.

3 . The system of claim 2 , wherein:

the proportional values are calculated by processing the error value with respect to time with a proportional gain coefficient;

the integral values are calculated by processing the error value with respect to time with an integral gain coefficient and an integral variable; and

the derivate values are calculated by processing the error value with respect to time with a derivative gain coefficient.

4 . The system of claim 1 , wherein the set of instructions, when executed by the processor, cause the processor to:

control a gas humidifier within the gas blender system, the gas humidifier configured to humidify the gas mixture delivered to the patient.

5 . The system of claim 4 , wherein the gas humidifier comprises:

a sterile water reservoir; and

a humidifier cartridge functionally coupled to the sterile water reservoir, the humidifier cartridge configured to humidify the gas mixture via a vaporization mechanism.

6 . The system of claim 5 , wherein the vaporization mechanism is ultrasonic vibration or heating to steam.

7 . The system of claim 5 , the gas humidifier further configured to:

measure a rate of sterile water consumption in the sterile water reservoir;

and

transmit the measured rate of the sterile water consumption to the processor, the measured rate of the sterile water consumption corresponding to a measure of humidity of the gas mixture delivered to the patient.

8 . The system of claim 1 , wherein the set of instructions, when executed by the processor, cause the processor to:

receive a target temperature value of the gas mixture delivered to the patient via the user interface; and

control a gas heater within the gas blender system using the target temperature value, the gas heater configured to heat the gas mixture delivered to the patient to the target temperature value.

9 . The system of claim 8 , the gas blender system further comprising a heat sensor configured to:

measure a temperature of the gas mixture delivered to the patient; and

transmit the measured temperature to the processor.

10 . The system of claim 9 , wherein the heat sensor is a thermistor.

11 . A computer implemented method for controlling a gas blender system to deliver a gas mixture with a target FiO 2 to a patient, the method comprising:

receiving, by a processor of the gas blender system, a target PaO 2 value from a user via a user interface;

receiving, by the processor, a first measured SpO 2 value from a pulse oximeter;

converting, by the processor, the first measured SpO 2 value to a first measured PaO 2 value using a first lookup table derived from a sigmoid shaped oxyhemoglobin dissociation curve;

calculating, by the processor, a first error value as a difference between the first measured PaO 2 and the target PaO 2 ;

processing, by the processor, the first error value to determine a first oxygen mixer control value, by executing an algorithm using at least one of proportional values, integral values, or derivative values;

receiving, by the processor, a second measured SpO 2 value from a regional oximeter functionally connected to the at least one processor and configured to measure cerebral blood oxygen saturation;

converting, by the processor, the second measured SpO 2 value to a second measured PaO 2 value using a second lookup table derived from a sigmoid shaped oxyhemoglobin dissociation curve;

calculating, by the processor, a second error value as a difference between the second measured PaO 2 and the target PaO 2 ;

processing, by the processor, the second error value to determine a second oxygen mixer control value, by executing an algorithm using at least one of proportional values, integral values, or derivative values;

and

if the system is operating in a first mode, outputting, by the processor, the first oxygen mixer control value to a blender controller and cause the gas blender system to deliver the gas mixture to the patient with the target FiO 2 value, or

if the system is operating in a second mode, outputting, by the processor, the second oxygen mixer control value to the blender controller and cause the gas blender system to deliver the gas mixture to the patient with the target FiO 2 value.

12 . The method of claim 11 , wherein the processing the error value comprises using proportional values, integral values, and derivative values.

13 . The method of claim 12 , wherein:

the proportional values are calculated by processing the error value with respect to time with a proportional gain coefficient;

the integral values are calculated by processing the error value with respect to time with an integral gain coefficient and an integral variable; and

the derivate values are calculated by processing the error value with respect to time with a derivative gain coefficient.

14 . The method of claim 11 , further comprising controlling a gas humidifier within the gas blender system to humidify the gas mixture delivered to the patient.

15 . The method of claim 14 , comprising:

humidifying the gas mixture via a vaporization mechanism in a humidifier cartridge functionally coupled to a sterile water reservoir.

16 . The method of claim 15 , wherein the vaporization mechanism is ultrasonic vibration or heating to steam.

17 . The method of claim 15 , comprising:

measuring a rate of sterile water consumption in the sterile water reservoir;

and

transmitting the measured rate of the sterile water consumption to the processor, the measured rate of the sterile water consumption corresponding to a measure of humidity of the gas mixture delivered to the patient.

18 . The method of claim 11 , further comprising:

receiving, by the processor, a target temperature value of the gas mixture delivered to the patient via the user interface; and

controlling, by the processor, a gas heater within the gas blender system using the target temperature value to heat the gas mixture delivered to the patient to the target temperature value.

19 . The method of claim 18 , further comprising

measuring a temperature of the gas mixture delivered to the patient using a heat sensor and transmitting the measured temperature to the processor.

20 . The method of claim 19 , wherein the heat sensor is a thermistor.

Assignments (2)
SECURITY INTEREST Recorded Apr 20, 2026
From: VAPOTHERM, INC.
To: PERCEPTIVE CAPITAL SOLUTIONS HOLDINGS LP
Reel/Frame 075477/0224 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2024
From: TAUBE, JOHN C.
To: VAPOTHERM, INC.
Reel/Frame 068001/0130 →
Continuity (2)
Continuation 16672638 · Nov 4, 2019
Related Publication 20240285887A1 · Aug 29, 2024
References Cited (126)
US 2414747A · Kirschbaum · 1947 [cited by applicant]
US 3734091A · Taplin · 1973 [cited by applicant]
US 4325413A · Lenhart et al. · 1982 [cited by applicant]
US 4584996A · Blum · 1986 [cited by applicant]
US 4665911A · Williams et al. · 1987 [cited by applicant]
US 4765340A · Sakai et al. · 1988 [cited by applicant]
US 4889116A · Taube · 1989 [cited by applicant]
US 5003985A · White et al. · 1991 [cited by applicant]
US 5103814A · Maher · 1992 [cited by applicant]
US 5178151A · Sackner · 1993 [cited by applicant]
US 5388575A · Taube · 1995 [cited by examiner]
US 6186142B1 · Schmidt et al. · 2001 [cited by applicant]
US 6561187B2 · Schmidt et al. · 2003 [cited by applicant]
US 7329038B2 · Hashiba · 2008 [cited by applicant]
US 7802571B2 · Tehrani · 2010 [cited by applicant]
US 8194944B2 · Tivig et al. · 2012 [cited by applicant]
US 8434481B2 · Ogilvie et al. · 2013 [cited by applicant]
US 8434483B2 · Patel et al. · 2013 [cited by applicant]
US 8434484B2 · Patel · 2013 [cited by applicant]
US 8434523B2 · Suharno · 2013 [cited by applicant]
US 8801619B2 · Baker, Jr. et al. · 2014 [cited by applicant]
US 10007238B1 · Taube · 2018 [cited by examiner]
US 11458270B2 · Landis et al. · 2022 [cited by applicant]
US 11612706B2 · Taube · 2023 [cited by applicant]
US 12268817B2 · Niland et al. · 2025 [cited by applicant]
US 20010035185A1 · Christopher · 2001 [cited by applicant]
US 20020017302A1 · Fukunaga et al. · 2002 [cited by applicant]
US 20030013980A1 · Starr et al. · 2003 [cited by applicant]
US 20030211244A1 · Li et al. · 2003 [cited by applicant]
US 20030216285A1 · Dumont et al. · 2003 [cited by applicant]
US 20040054261A1 · Kamataki et al. · 2004 [cited by applicant]
US 20040230108A1 · Melker et al. · 2004 [cited by applicant]
US 20050051168A1 · DeVries et al. · 2005 [cited by applicant]
US 20050109340A1 · Tehrani · 2005 [cited by applicant]
US 20050222503A1 · Dunlop et al. · 2005 [cited by applicant]
US 20050247311A1 · Vacchiano et al. · 2005 [cited by applicant]
US 20070137107A1 · Barnicki · 2007 [cited by applicant]
US 20080156328A1 · Taube · 2008 [cited by applicant]
US 20080183057A1 · Taube · 2008 [cited by applicant]
US 20090090363A1 · Niland et al. · 2009 [cited by applicant]
US 20090305214A1 · Pybus et al. · 2009 [cited by applicant]
US 20100175695A1 · Jamison · 2010 [cited by applicant]
US 20100224191A1 · Dixon et al. · 2010 [cited by applicant]
US 20110152648A1 · Rustick · 2011 [cited by applicant]
US 20110190611A1 · Rabi · 2011 [cited by applicant]
US 20110200392A1 · Moncrief, III · 2011 [cited by applicant]
US 20110319783A1 · Lindholt et al. · 2011 [cited by applicant]
US 20120016219A1 · Fujii · 2012 [cited by applicant]
US 20120090611A1 · Graboi et al. · 2012 [cited by applicant]
US 20120118285A1 · Wondka et al. · 2012 [cited by applicant]
US 20120325207A1 · Fromage · 2012 [cited by applicant]
US 20130030267A1 · Lisogurski et al. · 2013 [cited by applicant]
US 20130174841A1 · McAuley et al. · 2013 [cited by applicant]
US 20130263855A1 · Tivig et al. · 2013 [cited by applicant]
US 20130276780A1 · Tobia et al. · 2013 [cited by applicant]
US 20140166005A1 · Tatkov et al. · 2014 [cited by applicant]
US 20150059754A1 · Chbat et al. · 2015 [cited by applicant]
US 20150107588A1 · Cheung et al. · 2015 [cited by applicant]
US 20150320953A1 · Acker et al. · 2015 [cited by applicant]
US 20160121063A1 · Tatkov et al. · 2016 [cited by applicant]
US 20160193438A1 · White et al. · 2016 [cited by applicant]
US 20160213879A1 · Parthasarathy et al. · 2016 [cited by applicant]
US 20160361508A1 · Cohen · 2016 [cited by applicant]
US 20170143538A1 · Lee et al. · 2017 [cited by applicant]
US 20180280645A1 · Lellouche et al. · 2018 [cited by applicant]
US 20200170513A1 · Walker · 2020 [cited by applicant]
US 20210128032A1 · Taube · 2021 [cited by applicant]
US 20210353158A1 · Landis et al. · 2021 [cited by applicant]
US 20220331548A1 · Gulley et al. · 2022 [cited by applicant]
US 20220347423A1 · Babbage et al. · 2022 [cited by applicant]
US 20230022107A1 · Gulley et al. · 2023 [cited by applicant]
US 20230277798A1 · Adametz et al. · 2023 [cited by applicant]
US 20230321368A1 · Power · 2023 [cited by applicant]
US 20240033456A1 · Gray et al. · 2024 [cited by applicant]
US 20240082521A1 · Gulley · 2024 [cited by applicant]
US 20240207553A1 · Gulley · 2024 [cited by applicant]
US 20240245874A1 · Leonard et al. · 2024 [cited by applicant]
US 20240252772A1 · Lui et al. · 2024 [cited by applicant]
US 20240277966A1 · Rapoport et al. · 2024 [cited by applicant]
US 20240285887A1 · Taube · 2024 [cited by applicant]
US 20240379221A1 · Seekup et al. · 2024 [cited by applicant]
US 20250025650A1 · Russell et al. · 2025 [cited by applicant]
US 20250325766A1 · Gulley et al. · 2025 [cited by applicant]
CA 2545570A1 · 2005 [cited by applicant]
CA 2691377A1 · 2009 [cited by applicant]
CA 2827253A1 · 2012 [cited by applicant]
ES 2267141T3 · 2007 [cited by applicant]
WO 9624402A1 · 1996 [cited by applicant]
WO 2002056931A2 · 2002 [cited by applicant]
WO 2005038690A2 · 2005 [cited by applicant]
WO 2005051280A2 · 2005 [cited by applicant]
Branson, et al., “Is Humidification Always Necessary During Noninvasive Ventilation in the Hospital?”, Respiratory Care, vol. 55, No. 2 (pp. 209-216), published Feb. 2010, 8 pages. [cited by applicant]
Anon., “Critical Care Therapy and Respiratory Care Section”, National Institutes of Health, published Aug. 1997 and revised Nov. 2000, 4 pages. [cited by applicant]
Sano, et al., “Adaptive control of arterial oxygen pressure of newborn infants under incubator oxygen treatments”, IEE Proceeding, vol. 132, Pt. D., No. 5 (pp. 205-211), published Sep. 1985, 7 pages. [cited by applicant]
Anon., “Analog Dialogue: Pulse Oximeter”, Analog Devices, Inc., (1995-2014), retrieved from the Internet <URL: https://www.analog.com/en/resources/analog-dialogue/articles/pulse-oximeter-uses-aduc7024-microconverter.htm… [cited by applicant]
Soto, et al., “Automatic Ventilation Control”, NXP Beyond Bits Health and Safety, Issue 4 Summer 2009 (pp. 32-34), undated, retrieved from the Internet on Sep. 17, 2014, <URL: chrome-extension://efaidnbmnnnibpcajpcglcle… [cited by applicant]
Elleau, et al., “Helium-Oxygen mixture in respiratory distress syndrome: a double blind study”, J Pediatr., 122(1):132-6, Abstract, published Jan. 1993 and revised Aug. 1993, 1 page. [cited by applicant]
Davies, et al., “Inspired Gas Temperature in Ventilated Neonates”, Pediatric Pulmonology 38:50-54, published 2004, 8 pages. [cited by applicant]
Carter, et al., “Evaluation of heliox in children hospitalized with acute sever asthma. A randomized crossover trial”, Abstract, Chest., 109(5):1256-61, published May 1996, Retrieved from Internet <URL: https://pubmed.n… [cited by applicant]
Adawy, et al., “Design of Fuzzy Controller for Supplying Oxygen in Sub-acute Respiratory Illnesses”, IJCSI, vol. 9, Issue 3, No. 1 (pp. 192-206), published May 2012, 15 pages. [cited by applicant]
Kass, et al., “Heliox therapy in acute severe asthma.”, Abstract, Chest., 107(3):757-60, published Mar. 1995, 2 pages. [cited by applicant]
Kudukis, et al., “Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children”, Abstract, J Pediatr., 130(2):217-24, published Feb. 1997, 2 pages. [cited by applicant]
Lu, et al., “Helium-Oxygen in Treatment of Upper Airway Obstruction”, Clinical Reports, Anestheology, vol. 45, No. 6, (pp. 678-680), published Dec. 1976, 3 pages. [cited by applicant]
Manthous, et al., “Heliox improves pulsus paradoxus and peak expiratory flow in nonintubated patients with severe asthma”, Am J Respir Crit Care Med., Abstract, 151(2 Pt 1):310-4, published Feb. 1995, 2 pages. [cited by applicant]
Martin-Barbaz, et al., “Use of helium oxygen mixtures in status asthmaticus”, Abstract, Rev Pneumol Clin. 43 (4): 186-9, published 1987, 1 page. [cited by applicant]
Anon., “MR850 Respiratory Humidifier”, Fisher & Paykel Healthcare, REF 185042343, Rev. J, dated Aug. 2012, 3 pages. [cited by applicant]
Anon., “Oxygen Saturation”, undated, downloaded on Aug. 20, 2014, 4 pages. [cited by applicant]
Alkurawy, “Design of an Efficient Controller for Arterial Oxygen Saturation in Neonatal Infants”, PhD Thesis, University of Missouri-Columbia, dated Dec. 2013, 114 pages. [cited by applicant]
Sauder, et al., “Helium-oxygen and conventional mechanical ventilation in the treatment of large airway obstruction and respiratory failure in an infant”, Abstract, South Med J. 84(5):646-8, published May 1991, 1 page. [cited by applicant]
Shiue, et al., “The use of helium-oxygen mixtures in the support of patients with status asthmaticus and respiratory acidosis”, J Asthma, Abstract, 26(3):177-80, published 1989, 1 page. [cited by applicant]
Swidwa, et al., “Helium-oxygen breathing in severe chronic obstructive pulmonary disease”, Abstract, Chest, 87 (6):790-5, published Jun. 1985, 2 pages. [cited by applicant]
Panchal, et al., “Feedback-Controlled System to Titrate Oxygen Delivery”, Drexel University, Progress Report, BMES 492, dated 2014, 41 pages. [cited by applicant]
Ardizzoni, “The incredible versatile op amp in medical apps”, Electronic Products, Analog devices, retrieved from the Internet <URL: https://www.electronicproducts.com/the-incredible-versatile-op-amp-in-medical-apps/>, … [cited by applicant]
Wolfson, et al., “Mechanics and energetics of breathing helium in infants with bronchopulmonary dysplasia.”, Abstract, J Pediatr., 104(5):752-7, published May 1984, 1 page. [cited by applicant]
USPTO, Non-Final Office Action for corresponding U.S. Appl. No. 16/003,508, dated Jun. 27, 2019, 18 pages. [cited by applicant]
USPTO, Non-Final Office Action for corresponding U.S. Appl. No. 14/602,392 dated Oct. 3, 2017, 19 pages. [cited by applicant]
USPTO, Final Office Action for corresponding U.S. Appl. No. 14/602,392, dated Mar. 1, 2018, 22 pages. [cited by applicant]
ISA/EP, International Search Report and Written Opinion for corresponding International Patent Application No. PCT/US2020/057823, mailed Jan. 28, 2021, 12 pages. [cited by applicant]
ISA/RU, International Search Report and Written Opinion for corresponding International Patent Application No. PCT/US2020/062118, mailed Mar. 11, 2021, 7 pages. [cited by applicant]
USPTO, Non-Final Office Action for corresponding U.S. Appl. No. 16/722,722, dated Dec. 22, 2020, 17 pages. [cited by applicant]
WIPO, International Preliminary Report on Patentability for corresponding PCT Patent Application No. PCT/US2020/057823, dated May 10, 2022, 9 pages. [cited by applicant]
WIPO, International Preliminary Report on Patentability for corresponding PCT Patent Application No. PCT/US2020/062118, dated May 17, 2022, 6 pages. [cited by applicant]
USPTO, Non-Final Office Action for corresponding U.S. Appl. No. 17/403,192, dated Oct. 6, 2022, 30 pages. [cited by applicant]
USPTO, Final Office Action for corresponding U.S. Appl. No. 17/403,192, dated Mar. 21, 2023, 16 pages. [cited by applicant]
USPTO, Non-Final Office Action for corresponding U.S. Appl. No. 16/672,638, dated Jul. 28, 2022, 14 pages. [cited by applicant]
USPTO, Final Office Action for corresponding U.S. Appl. No. 16/672,638, dated Dec. 9, 2022, 21 pages. [cited by applicant]